Trials / Completed
CompletedNCT02580201
A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Fidec Corporation · Academic / Other
- Sex
- All
- Age
- 5 Weeks – 5 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety (serious adverse events \[SAEs\]), and severe adverse events \[AEs\] (grade 3 according to CTCAE 4.03) after one dose of SABIN tOPV in 1-5 year-old children and three doses of SABIN tOPV in 6 week-old infants, and immunogenicity (seroprotection rates for all 3 serotypes) 28 days after three doses of SABIN tOPV in vaccine-naïve infants.
Detailed description
This will be a single center, open study in children (aged 1 to 5 years) and vaccine-naïve infants, as follows: 50 OPV-vaccinated children aged 1 to 5 years to receive 1 dose of tOPV (Group 1); 104 vaccine-naïve infants to receive 3 doses of tOPV administered 28 days apart (Group 2)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Oral Polio Vaccine | Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment. The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container. |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2016-07-01
- Completion
- 2016-08-11
- First posted
- 2015-10-20
- Last updated
- 2023-04-18
- Results posted
- 2020-09-01
Source: ClinicalTrials.gov record NCT02580201. Inclusion in this directory is not an endorsement.